Scientific Health Development

Scientific Health Development ("SHD") is a boutique investment company located in Dallas, TX. SHD invests in early-stage, innovative healthcare-related technologies and products.


Recent News

Podimetrics Raises $13.4 Million to Expand Innovative Solution for Diabetes Complications

Somerville, MA - May 9, 2019 -- Podimetrics, a care management company with the leading solution to help prevent costly and deadly diabetic foot ulcers (DFUs), today announced it has closed a $13.4 million Series B funding round. Participants included Rock Health, Norwich Ventures, and Scientific Health Development. The new funding will accelerate Podimetrics’ growing presence within the Veterans Affairs (VA) health care system and commercial payers nationwide. For full story click here...

Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

Menlo Park, CA - April 30, 2019 -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and glaucoma – today announced the official commercial launch of TearCare® and the introduction of an aesthetically and ergonomically enhanced OMNI® Surgical System (which was initially launched in February 2018). For full story click here...

Channel Medsystems® Receives U.S. FDA Approval of the Cerene® Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding

Emeryville, CA - April 2, 2019 -- Channel Medsystems®, a company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that the U.S. Food and Drug Administration (FDA) has approved the Cerene® Cryotherapy Device as a new approach to treating heavy menstrual bleeding. For full story click here...

Clinical Study Demonstrates Long Term IOP Reduction With The OMNI® Surgical System Predicate Device (TRAB®360) In Micro-Invasive Glaucoma Surgery

Menlo Park, CA - March 14, 2019 -- A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI® Surgical System’s Predicate Devices (TRAB®360) provides a favorable safety profile and substantial long-term reductions in both intraocular pressure (IOP) and IOP-lowering medications. For full story click here...

First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension

Berwyn, PA - February 21, 2019 -- Complexa Inc. today announced dosing of the first patient in PRIMEx, a Phase 2 clinical trial evaluating the safety and efficacy of two doses of the company’s lead candidate, CXA-10, to treat pulmonary arterial hypertension (PAH). PAH is a rare, progressive disease characterized by high blood pressure in the vessels that carry blood from the right side of the heart to the lungs, which can compromise the normal function of the heart. For full story click here...

FierceMedTech names Potrero Medical as one of its "Fierce 15" Med Tech Companies of 2018

Hayward, CA - February 11, 2019 -- Potrero Medical announced today that it has been named by FierceMedTech as one of 2018’s Fierce 15 medtech companies, designating it as one of the most promising private med tech companies in the industry. For full story click here...

Predictive Health Company Potrero Medical Closes $26.6 Million in Oversubscribed Series C Financing

Hayward, CA - July 9, 2018 -- Potrero Medical, Inc., a predictive health company focused on using smart sensors and analytics for early detection of critical illnesses, announced today the closing of a $26.6 million Series C financing. The financing was led by China-focused healthcare investment firm GT Healthcare Capital Partners and Silicon Valley-based Sonder Capital. The funding will support further commercialization efforts of the company's flagship product, the Accuryn® Monitoring System. For full story click here...

First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis

Berwyn, PA - June 1, 2018 -- Complexa Inc. today announced dosing of the first patient in FIRSTx, a Phase 2 clinical trial evaluating the safety and efficacy of the company’s lead candidate, CXA-10, to treat primary focal segmental glomerulosclerosis (FSGS). FSGS is a rare and severe form of kidney disease that can lead to permanent kidney damage and even kidney failure. CXA-10 is the first drug of a novel pharmacological class of oral compounds called nitrated fatty acids (NFAs) being developed for the treatment of diseases associated with fibrosis and inflammation. For full story click here...

Boston Therapeutics Announces Strategic Acquisition of CureDM

Lawrence, MA - February 13, 2018 -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to their portfolio. The CureDM islet-growing peptide, HIP2B, has demonstrated clinical efficacy for type 2 diabetes by improving first phase insulin release, increasing fasting insulin levels and insulin secretion rates. Boston Therapeutics is committed to development of treatments that impact endogenous glucose regulation. This bold move to acquire the worldwide exclusive rights to commercialize HIP2B, alongside current product offerings, is a key part of the long term plan to alleviate the health, economic and quality of life burden of diabetes. For full story click here...

Procyrion raises $16m in Series C to support Aortix intra-aortic heart pump

Houston, TX - February 1, 2018 -- Procyrion said earlier this week it raised $16 million in a Series C round of funding to support its Aortix catheter-deployed, intra-aortic heart pump designed for ambulatory use. The round was led by an affiliate of Fannin Partners and joined by existing investors Scientific Health Development, the State of Texas and an undisclosed strategic investor, the Houston-based company said. For full story click here...

Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System

Menlo Park, CA - January 4, 2018 -- Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated for the delivery of controlled volumes of viscoelastic fluid as well as the cutting of trabecular meshwork tissue. In addition, the company announced three key hires who possess proven leadership capabilities and industry experience to advance the commercial strategy and build out its senior leadership team. For full story click here...